Zimecki M, Schnaper H W, Wieczorek Z, Webb D R, Pierce C W
Department of Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Immunopharmacology. 1990 Jan-Feb;19(1):39-46. doi: 10.1016/0162-3109(90)90025-a.
IL-1-induced leukocytosis was inhibited or blocked in a dose-dependent manner by SIRS, an antigen-nonspecific suppressive lymphokine, when administered intravenously or per os to CBA mice. Timing experiments showed that SIRS effectively inhibited the leukocytosis when administered within 30 minutes of the IL-1. An antipyrogenic activity of SIRS was observed in rabbits injected intravenously with LPS. SIRS, given intravenously in one or two doses, markedly reduced LPS-induced fever. SIRS (2000 units) was a more effective antipyretic agent than aspirin (3 mg/kg body weight, intramuscularly). The results suggest that SIRS may be a potential drug for use in IL-1-mediated disorders.
当静脉内或经口给予CBA小鼠时，抗原非特异性抑制性淋巴因子SIRS以剂量依赖的方式抑制或阻断白细胞介素-1诱导的白细胞增多。时间实验表明，当在白细胞介素-1注射后30分钟内给予SIRS时，它能有效抑制白细胞增多。在静脉注射脂多糖的兔子中观察到了SIRS的解热活性。静脉注射一剂或两剂SIRS能显著降低脂多糖诱导的发热。SIRS（2000单位）比阿司匹林（3毫克/千克体重，肌肉注射）是更有效的解热剂。结果表明，SIRS可能是一种用于治疗白细胞介素-1介导疾病的潜在药物。
